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T
his is the ﬁrst of a series of articles
based on presentations at the Amer-
ican Diabetes Association Scientiﬁc
Sessions held 6–10 June 2008 in San
Francisco, California.
Type 1 Diabetes and the -Cell
Matthias von Herrath (La Jolla, CA) re-
ceived the American Diabetes Association
(ADA) 2008 Outstanding Scientiﬁc
Achievement Award for his research on
approachesto-cell–speciﬁcimmunein-
terventions for type 1 diabetes. He began
with a discussion of the evidence of a role
of viral infections in the development of
type 1 diabetes. In experimental models,
viral infection may either accelerate or re-
tard the immunologic process leading to
type 1 diabetes. He pointed out that al-
though type 1 diabetes is clearly an auto-
immune disease, because a pancreas
transplanted from an unaffected to a type
1diabeticidenticaltwinisassociatedwith
an immune response and rejection, the
cause of autoreactivity is uncertain. Envi-
ronmental factors are likely implicated:
viral and also nutritional. Furthermore,
the degree of islet inﬂammation in type 1
diabetes is rather mild, which may shed
light on how viral infections might con-
tributetothediseaseprocessbecauseonly
3–4% of islets in pre-diabetic patients—
and not a great deal more at the time of
diagnosis—are affected by insulitis. Ap-
proaches to prevention might include
modiﬁcation of genes that predispose to
diabetes and their gene products or mod-
iﬁcation of environmental factors, but
emerging evidence suggests that type 1
diabetes is polygenic, with protective as
well as enhancing genes, not all of which
can suitably be altered.
Curing type 1 diabetes might be ac-
complished with an unlimited -cell
source, perhaps from stem cells, to make
islet transplantation more generally feasi-
ble.-Cellaugmentationmaybeaninter-
mediate goal for which islet transplant
protocols not ﬂawed by loss of islets after
3–4 years must be developed, perhaps
by eliminating preexisting autoaggressive
T-cells. Ongoing trials to prevent and
cure recent-onset type 1 diabetes with
immune-based and combinatorial ther-
apies need to achieve durable immune
suppressionwhileatthesametimepreserv-
ingoverallimmunitytopreventmalignancy
and infection ultimately, an approach must
be developed to strengthen the body’s own
-cell immunoregulatory responses.
Addressing the issue of the contribu-
tion of viral infections, von Herrath re-
viewed the hypothesis that viruses may
trigger or enhance type 1 diabetes, noting
that viruses can directly infect and lyse
-cells (1). Epidemiological evidence sug-
geststhatsuchrapidcasesoftype1diabetes
are uncommon. An alternate hypothesis,
that viruses mimic -cell antigens, appears
unlikely,asviralinfectionsdonotappearto
precipitate type 1 diabetes in otherwise in-
tact animals (2). Rather, he suggested the
“fertile ﬁeld” hypothesis that, in the setting
of genetic predisposition to anti-islet auto-
immunity, a viral infection can “push a pre-
diabetic animal” into diabetes status.
Upregulation of major histocompatibility
complex(MHC)classImoleculesandinter-
feron-maybefoundinhumanisletsinthe
absence of immune inﬁltration, which is
possibly a signature of viral infection, von
Herrath explained. The absence of inﬂam-
matoryinﬁltratesuggeststhatthisisdirectly
caused by viral infection, which further
supportsthenotionofthevirus’persistence
because these markers typically downregu-
late rapidly after infections resolve. As a
consequence of virally induced, interferon-
dependent increased MHC class I expres-
sion by -cells, autoaggressive CD8
cytotoxicT-cellsareseeninisletsinarodent
model (3), along with -cell destruction,
while -cells not expressing MHC I “are in-
visible to the immune system.” Thus, viral
infection may lead to type 1 diabetes by
making an underlying autoimmune state
manifest. von Herrath concluded that spe-
ciﬁc -cell trophic viral infections “do not
cause but substantially contribute” to the
development of type 1 diabetes. Human is-
lets can in this setting express MHC I and
interferons even without an inﬂammatory
inﬁltrate in individuals genetically at risk.
Von Herrath described, however, an-
other phenomenon, where under certain
circumstances viruses can prevent type 1
diabetes, supporting the “hygiene hypothe-
sis”thattype1diabetesoccursindeveloped
countries where the immune system has a
lesser opportunity to be appropriately
trained. He reviewed a study in which ac-
celeration versus abrogation of diabetes in
an animal model depended on the speciﬁc
time of infection, with infection before or
after a speciﬁc time preventing rather than
causing diabetes in a type 1 diabetes–prone
animal model. Regulatory T-cells reduce
theimmuneresponse,augmentingproduc-
tion of CD4/CD25
 T-cells leading to pro-
duction of interleukin (IL)-4 and IL-10. In
diabetes-prone models, administration of
systemic viral infection–induced regulatory
T-cells to at-risk mice will transfer the pro-
tective effect, with suppression of CD8 T-
cell response to viral infections in part
dependent on transforming growth factor
(TGF)-production.Viralinfectionalsoin-
creases IL-10 and interferon-, which usu-
ally play proinﬂammatory roles. Thus,
TGF- and other protective factors includ-
ing tumor necrosis factor (TNF)- down-
regulate the antiviral immune response,
which normally occurs as a virus is being
cleared to reduce the systemic immune re-
sponse. The contraction of the antiviral im-
mune response “pulls along with itself the
cells that are attacking the islets.” The two
components for clinical treatment will be
elimination of autoreactive T-cells and the
achievement of long-term tolerance
through induction of regulatory T cells.
Combinationtherapieswillbeneededtoin-
crease efﬁcacy while reducing adverse ef-
fects of immunosuppression. von Herrath
reviewed the effect of anti-CD3 antibodies
and vaccination with -cell antigens and
found that they have limited effect but ap-
pear safe, suggesting that the combination
of both approaches may be more effective.
NotingthatinductionofeffectorT-cells
(Teffs)andregulatoryT-cells(Tregs)occurs
during infection, inﬂammation, and auto-
immunity, von Herrath addressed the un-
derstanding of “switch factors” such as
speciﬁc cytokines that will favor Tregs
rather than Teff “to recruit your own im-
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study of subcutaneous administration of
GAD leading to activation and proliferation
of Tregs. Cytokines such as TGF-, IL-4,
and IL-10 can modulate this process, gen-
erating antigen-presenting cells that reduce
TeffsandaugmentgenerationofTregs.One
doesnotneed,then,tousethepreciseauto-
antigen driving the immune response to
produce regulatory T-cells leading to long-
termtolerancewhileavoidingsystemicside
effects. In animal models, it is possible to
show complete and permanent protection
with administration of oral insulin, with
peri-insulitis representing recruitment of
protective Tregs. Not all -cell proteins are
suitable for inducing Tregs, so for human
treatment, it may be necessary to develop
tools for determining which islet antigen
and what dosage are optimal for a given pa-
tient, as well as to deﬁne the appropriate
time for administration. Dose appears to
play a crucial role, with administration of
porcine and human insulin in animal mod-
els appearing protective only in a speciﬁc
dosage range. Intranasal insulin protects
young mice but precipitates diabetes in
older mice, suggesting the importance
of timing, although it may be possible
with combination therapies or use of
suitable adjuvants to ensure that regu-
latorybutnotislet-attackingT-cellswill
be produced.
von Herrath again noted the potential
synergy between anti-CD3 and antigen-
speciﬁc immunotherapy, suggesting that
such an approach may circumvent side ef-
fects and enhance efﬁcacy, with encourag-
ing results in animal studies showing
reversal of recent-onset diabetes—which is
much more difﬁcult to attain than preven-
tion. Hyperglycemic mice are refractory to
combination therapy, suggesting that opti-
mal glycemic regulation characterizes indi-
viduals with potential beneﬁt either as a
marker of the degree of severity of the dia-
betes or because of intrinsic beneﬁt of
improved glycemia. Both arms of the
combined treatment increase Treg and
resultinlossofaggressiveCD8T-cells.Inan
animal model, increased induction of CD4/
CD25 Tregs and decreased CD8 Teff in
spleen and pancreatic lymph nodes were
seen after combined treatment. In a small
clinical study, type 1 diabetic patients
with higher IL-10 and Tregs had better
subsequent glycemic control, suggesting
that vaccines increasing Tregs might im-
prove glycemia. In a study with intransal
proinsulin, proinsulin-speciﬁc adaptive
Tregs were seen, with enhanced disease
prevention when proinsulin immuniza-
tion was combined with a short course of
anti-CD3. Other combinations of immuni-
zation with systemic immune modulators
have been tested, and the combination of
oral and intranasal insulin showed synergy
as well.
In silico simulation of optimal treat-
ment regimens may allow optimization of
experimental and, later, treatment parame-
ters.Intwoongoingintranasalinsulintrials,
the one with daily administration appears
ineffective, while less frequent dosing may
be more effective—an outcome predicted
by such a simulation. Treatment of type 1
diabetes will require greater availability of
human pancreases and better in vivo imag-
ing of pancreatic islets. von Herrath sug-
gested the need to test combination
therapies before single drugs have been ap-
proved, given his perception that single
treatments for type 1 diabetes will be inef-
fective. The development of biomarkers to
predict success of an intervention would be
useful, with longitudinal T cell studies po-
tentially such markers. “The ultimate goal,”
vonHerrathconcluded,“shouldbeanearly
childhood vaccine.”
InalectureattheMountSinaiDiabetes
Conference on 23 October 2008, Kevin
Herold (New Haven, CT) discussed anti-
CD3 treatment of type 1 diabetes. Recalling
the classic concept that type 1 diabetes rep-
resents the summation of many years of
progressive-celldestruction,withthedis-
ease becoming clinically manifest after loss
of almost all insulin production, he sug-
gested that now it appears that between 30
and 50% of -cells remain present at the
onsetofthedisease—farmorethanthought
previously. This offers the possibility that
immune treatment may markedly amelio-
rate the subsequent course, given the close
associationbetweenendogenousinsulinse-
cretory capacity and glycemic control. CD3
is the principal T-cell antigen recognition
receptor, and CD4 and CD8 are additional
T-cell molecules involved in antigen recog-
nition. Histological examination of islets in
human type 1 diabetes involves CD8
 and
CD3
T-cellsandrelativelyfewCD4T-cells
(4) in contrast to the ﬁndings in the non-
obese diabetic (NOD) mouse (a commonly
used animal model), implying that treat-
ment approaches based on the model may
not readily be extrapolated to man.
The ﬁnding of autoantibodies to multi-
ple islet antigens, including GAD, insulin,
insulinoma-associated protein 2, and anti-
islet cell antibodies is typical at clinical dia-
betes onset, although these antibodies are
not required for -cell destruction, for
which the main effectors are reactive T-
cells.TheapproachthatHeroldhastakenis
touseantibodiesdirectedattheε -portionof
CD3, which lead to disease reversal with a
peri-islet regulatory lymphocyte inﬁltrate
seen histologicaly. The initially used anti-
CD3 preparation, muromonab, is a mouse
antibodythatcausestoxicityfromT-cellac-
tivation; currently used modiﬁed human-
ized molecules do not show Fc binding
leading to far less T-cell proliferation and
interferon- production, with higher levels
ofIL-10andonlytransientT-celldepletion.
In 21 new-onset type 1 diabetic patients
treatedfor14days,TNF-andIL-5,-6,and
-10levelsrose,withamildcytokine-release
syndrome of headache, fever, and rash oc-
curring and one patient developing throm-
bocytopenia. Insulin requirements were
stable with treatment while progressively
increasing in control patients. C-peptide
levels fell by 50% at 1 year and by 75% at 2
years in control subjects but were stable or
even increased at 1 year in 15 of the treated
patients(5),thoughthendecreasing50%at
2 years, suggesting that a second course of
treatmentat1yearmightbeappropriate(an
approach now being studied).
Another set of studies will involve
treatment of pre-diabetic relatives with
abnormal glucose tolerance and multiple
positive autoantibodies, and treatment of
patients with type 1 diabetes present for
4–12 months is also being explored.
CD8
 T-cell levels increase with treat-
ment, indicating the presence of regula-
tory T-cells that appear to reduce the
activity of cytotoxic T-cells. TNF- may
be responsible for this effect, which can
be blocked in vitro by incubation with
anti–TNF-. Herold showed evidence
that as a result of anti-CD3 treatment,
rather than elimination of diabetes-
speciﬁc T-cells reactive to islet autoanti-
gens, the number of such cells rise over
the ﬁrst 3 months after treatment. These
may be markers of CD8
 regulatory T-
cells. Studies with otelixizumab, a related
anti-CD3 compound, have shown similar
effects, and anti-CD20 is being studied in
animal models.
A ﬁnal question is whether -cell re-
generation can be demonstrated after
anti-CD3 treatment. In NOD mice, it ap-
pears that 10% of -cells are newly pro-
duced from precursor elements, with many
of the remaining new cells appearing to be
generated from previously dysfunctional
-cells expressing GLUT2 but not insulin.
Heroldnotedthatexenatide,ratherthanin-
creasing -cell regeneration, seems to in-
crease insulin content of the previously
dysfunctional cells, thus appearing to be a
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type 1 diabetes. There may be an effect of
modest levels of postprandial hyperglyce-
mia increasing -cell regeneration; how-
ever, above a certain level of glycemia,
glucose toxicity effects predominate.
Several studies presented at the ADA
meeting shed further light on causes and
approaches to treatment of type 1 diabe-
tes. Ferrannini et al. (abstract 150) ana-
lyzed characteristics of type 1 diabetes
development in 325 islet cell autoanti-
body-positive, nondiabetic, ﬁrst-degree
relatives from the Diabetes Prevention
Trial-1 study, ﬁnding that among the 113
who had developed diabetes, impaired
-cell glucose sensitivity rather than a de-
ﬁciency in absolute insulin secretion rate
was the main predictor of progression,
with accelerated reduction in this param-
eter shortly before onset of diabetes.
Keenan et al. (abstract 173) found that
31% of 276 individuals with type 1 dia-
betes for 50 years had either GAD or
insulinoma-associated protein 2 antibod-
ies in association with higher C-peptide
levels, suggesting residual insulin pro-
ducing cells. One of the C-peptide–
positive patients required treatment with
an immunosuppressant (mycophenolate
mofetil) for an intercurrent illness and
had a 4.7-fold increase in peak C-peptide
and a 50% reduction in daily insulin dos-
age, raising the intriguing possibility of
beneﬁt of immune modulation many
yearsaftertype1diabetesonset.Luoetal.
(abstract 1596) reported that coculture of
human islets with allogenic bone marrow
cells stimulated islet growth, reduced
IL-1and-cellapoptosis,andincreased
PDX-1 expression, which suggests in-
creased -cell regeneration. Coad (ab-
stract1618),notingthat-cellshavebeen
observed in the biliary system of normal
mice and that there is similar embryolog-
ical origin of islets and biliary epithelium,
cultured mouse adult gall bladder epithe-
lium with adenoviral infection to express
the islet transcription factors showing in-
sulin mRNA and protein with increase in
release in response to glucose. Brown
et al. (abstract 227) showed progressive
increase in glucagon secretion during a
meal accompanying the reduction in C-
peptide secretion during the ﬁrst year af-
terdiagnosisin23type1diabeticpatients
(abstractnumbersrefertotheADAScien-
tiﬁc Sessions, Diabetes 57 [Suppl. 2],
2008).
Understanding of the normal -cell
and of the -cell in type 2 diabetes will
ultimately lead to improvement in the
abilitytotreatallformsofdiabetes.Saisho
et al. (abstract 1,588) studied pancreas at
autopsy within 12 h of death from 105
nondiabetic lean subjects aged 20–100
years and found that despite marked at-
rophy of the acinar pancreas from age 60
years with a corresponding increase in
pancreaticfat,mean-cellmassremained
remarkably constant, implying the exis-
tence of regulatory factors preserving
-cellsandthattheincreasedincidenceof
type 2 diabetes with aging is not due to
loss of -cell mass. From the same group,
Minh et al. (abstract 4) obtained pancre-
ata at autopsy from six nondiabetic preg-
nant women and nine nonpregnant
women, matched for age and prepreg-
nancy BMI, showing a tripling of -cell
massfromweek20to40ofgestationwith
signiﬁcantly more small islets and in-
creased numbers of cells positive for in-
sulin in pancreatic ducts without change
in -cell size. Horowitz et al. (abstract
246)showedopposingeffectsofprolactin
and glucocorticoids on -cell genes in-
cluding FoxO1, PGC1, PPAR, and
CPT-1 and on -cell GLUT2 expression,
insulin production, and fatty acid oxida-
tion, suggesting a role in the preservation
(and perhaps expansion) of -cell mass
and function during pregnancy. Clark
et al. (abstract 1,604) examined lipofus-
cin body accumulation (a feature of aging
thatoccursinlong-lived,postmitoticcells
such as neurons and cardiac myocytes) in
islet -cells obtained at surgery from bi-
opsy specimens of 42 nondiabetic and six
diabetic individuals and found a linear
increase in lipofuscin area with age in
islets from both diabetic and nondia-
betic patients, suggesting reduction in
turnover and neogenesis of -cells with
age. At age 20 years, 58% of cells did
notcontainlipofuscin,whileatage40
this was only seen in 15% of cells. The
authors commented that islets trans-
planted from older donors should be
studied to ascertain whether insulin se-
cretory function decreases.
Hypoglycemia
Smith et al. (abstract 577) compared 31
and 19 insulin-treated diabetic patients
whowereawareandunawareofhypogly-
cemia and found 75 and 43% adherence
to recommendations for changes in treat-
ment regimens, respectively, suggesting
that purely educational efforts may be in-
sufﬁcient to reduce behavioral and treat-
ment patterns leading to such episodes.
Choudhary et al. (abstract 580) studied
87 type 1 diabetic patients over a 9–12
month period and found those with im-
paired hypoglycemia awareness to have a
3.7-fold greater likelihood of severe hy-
poglycemia than those without impaired
awareness and to have 1.4 vs. 0.6 blood
glucose levels 65 mg/dl per week on
home capillary glucose monitoring, re-
spectively; 5-day continuous glucose
monitoring at the end of the study, how-
ever,failedtoshowsigniﬁcantlymoreep-
isodes of glucose 55 or 40 mg/dl.
Marrett et al. (abstract 586) analyzed self-
reported weight gain among 2,008 type 2
diabetic individuals who were not receiv-
ing insulin and were participating in the
U.S.NationalHealthandWellnessSurvey
2007. Weight gain during the prior year
of 10–20 pounds was reported by 47%
and of 20 pounds by 25% and corre-
lated with experience of more severe hy-
poglycemia, worry about hypoglycemia,
and reduced satisfaction with treatment.
Anumberofapproachesarebeingde-
veloped to address issues related to hypo-
glycemia. Page et al. (abstract 15) studied
10 type 1 diabetic patients during hypo-
glycemia either with or without ingestion
of medium chain triglycerides and found
that the supplement improved verbal
memory during hypoglycemia without
differences in glucose or counterregula-
tory hormone levels; plasma ketones and
free fatty acids were elevated during hy-
poglycemia in those receiving the supple-
ment. They (abstract 22) found that
glucagondecreasesinresponsetoamixed
meal or sulfonylurea in nondiabetic indi-
viduals but increases in type 1 diabetic
patients; Cooperberg and Cryer interpret
this to show that intraislet insulin (per-
haps among other -cell secretory
products) normally suppresses -cell
glucagon secretion, whereas in the ab-
sence of -cell secretion the -cell stim-
ulatory effects of nutrient and the
sulfonylureabecomemanifest.Leuetal.
(abstract20)foundthat,asexpected,an
episode of hypoglycemia reduced the
counterregulatory response to a second
episode the next day; this was pre-
vented by infusion of the opioid recep-
tor blocker naloxone during the initial
episode, suggesting that treatments
blocking opioid signaling may have
beneﬁt in individuals with hypoglyce-
mia unawareness. In contrast, Davis
et al. (abstract 21) administered the
-aminobutyric acid-A receptor agonist
alprazolam to 31 normal individuals
and showed blunting of epinephrine,
norepinephrine, muscle sympathetic
nerve activity, pancreatic polypeptide,
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terregulatory responses during insulin-
induced hypoglycemia the next day,
with worsening of the blunting induced
by hypoglycemia on the prior day.
Henry et al. (abstract 19) measured oc-
cipital cortical glucose uptake and
showed increased levels in a small
group of type 1 diabetic patients with
hypoglycemia unawareness, suggesting
this to be due to increased transport.
Puente et al. (abstract 16) subjected rats
to three consecutive days of moderate
hypoglycemia or control infusion and
found that 1 week after subsequent se-
vere hypoglycemia, neuronal damage
was greater in the control group. Bree et
al. (abstract 17; from the same group)
found, moreover, that severe hypergly-
cemia caused by streptozotocin 14 days
previously increased neuronal damage
from severe hypoglycemia.
The importance of in-hospital hypo-
glycemia is increasingly being addressed.
Siram et al. (abstract 18) reported that
among 1,641 patients admitted to an in-
tensive care unit, glucose levels of 40
mg/dl and, to a lesser extent, 40–69
mg/dl were associated with increased
likelihood of acute renal injury and mor-
tality; insulin administration reduced the
likelihood of both renal insufﬁciency and
mortality regardless of hypoglycemia, al-
thoughsubcutaneousappearedlesslikely
than intravenous insulin treatment to be
associated with improved outcome. Dhir
et al. (abstract 579) described 182 in-
hospital hypoglycemia episodes typically
occurringafter3daysinthehospital,with
risk factors including reduced nutritional
intake, major organ dysfunction, resolv-
inginfection,increasinginsulindose,and
decreasing steroid dose in 60, 31, 22, 12,
and 4% of cases, respectively. Natoli et al.
(abstract 578) analyzed a hospitalization
database of 103,813 diabetic patients
from 2000–2006 and found that those
experiencing glucose 70 mg/dl had a
58% greater likelihood of discharge to a
nursing facility, a 7% greater inpatient
mortality, and, on average, three addi-
tionalhospitaldayswith39%highercost.
Pittas et al. (abstract 500) reported on a
meta-analysis of 15 randomized trials of
intensive insulin therapy in 8,472 criti-
cally ill, hospitalized, nonpregnant adult
patients, with glycemic goal 103–186 vs.
139–260 mg/dl, and showed no differ-
ence in mortality but a 4.3-fold greater
likelihood of hypoglycemia.
Davidson et al. (abstract 576) re-
ported a meta-analysis of nine trials of
more than 1,600 type 2 diabetic individ-
uals receiving biphasic insulin aspart ver-
sus biphasic human insulin, showing a
55% reduction in major hypoglycemia
and50%reductioninnocturnalhypogly-
cemia with the former, although fasting
glucose was reduced 37% more with the
latter agent. A1C and body weight
changed similarly. Similarly, Hutchinson
et al. (abstract 582) analyzed 1,005 seri-
ous hypoglycemia occurrences among
11,813 type 2 diabetic individuals start-
ing insulin treatment and found a 28%
reduction in the risk of these events in
users of analog insulin compared with
users of human insulin who attained sim-
ilar mean A1C levels of 8.6–8.9%.
Type 1 diabetes epidemiology
Kahn et al. (abstract 317) analyzed
monthly distribution of birth dates of
9,146 diabetic patients in the U.S. who
were diagnosed at age 20 years and
were participating in the SEARCH for Di-
abetesinYouthStudy.Kahnetal.founda
4% excess diabetes incidence in May and
a 5% deﬁcit in November, suggestive of
early-life environmental exposures that
contribute to childhood diabetes.
Tuomilehto et al. (abstract 23) de-
scribed another temporal trend in type 1
diabetes. Incidence in Finnish children
aged 15 years increased from 32.2 to
64.7casesper100,000peopleinthegen-
eral population per year in 1980 and
2005,respectively;therateofincreaseap-
pears to have accelerated in the 1990s.
Johnson et al. (abstract 24) reported a
47% increase in prevalence of diabetes in
the province of Alberta, Canada, during
the past decade, with a particularly dra-
matic 93% increase among those age 1–4
years—suggestive of type 1 rather than
type 2 diabetes.
Obesity in type 1 diabetes and its
overlap with type 2 diabetes and insulin
resistance are gaining interest. Shay et al.
(abstract 900) found, as expected, that
euglycemic clamp insulin sensitivity was
approximately twice as great in 15 type 1
diabetic patients compared with that in
42 type 2 diabetic patients. Insulin sensi-
tivity more strongly correlated with BMI,
waist size, percent body fat, and triglycer-
ide level in the type 1 than in the type 2
diabetic group, while it was less strongly
associated with diastolic blood pressure.
Conway et al. (abstract 29) found that
baseline BMI was associated with 18-year
mortality in 655 type 1 diabetic patients
whose mean age and diabetes duration
were 28 and 19 years, respectively, at ini-
tial observation. During follow-up, how-
ever, underweight patients (BMI 20 kg/
m
2) had greater mortality, overweight
(25  BMI  30 kg/m
2) was protective,
and obesity (BMI 30 kg/m
2) was neu-
tral. The authors wondered whether the
apparent protection from weight gain
during follow-up reﬂected more insulin
use, with 7% of patients initially and 84%
at 18 years receiving 3 insulin doses/
day.
Acknowledgments— Z.T.B. has served on
speaker’s bureaus of Merck, NovoNordisk,
Lilly, Amylin, Daichi Sankyo, and Glaxo-
SmithKline; has served on advisory panels for
Medtronics, Takeda, Merck, AtherGenics, CV
Therapeutics, Daichi Sankyo, BMS, and Astra
Zeneca; holds stock in Abbott, Bard,
Medtronic, Merck, Millipore, Novartis, and
Roche; and has served as a consultant for No-
vartis,DainipponSumitomoPharmaAmerica,
Forest Laboratories, and Nastech. No other
potential conﬂicts of interest relevant to this
article were reported.
References
1. Yoon JW, Austin M, Onodera T, Notkins
AL: Isolation of a virus from the pancreas
of a child with diabetic ketoacidosis.
N Engl J Med 300:1173–1179, 1979
2. Christen U, Edelmann KH, McGavern
DB, Wolfe T, Coon B, Teague MK, Miller
SD, Oldstone MB, von Herrath MG: A vi-
ral epitope that mimics a self antigen can
acceleratebutnotinitiateautoimmunedi-
abetes. J Clin Invest 114:1290–1298,
2004
3. Filippi CM, Juedes AE, Oldham JE, Ling
E, Togher L, Peng Y, Flavell RA, von
Herrath MG: Transforming growth fac-
tor- suppresses the activation of CD8

T-cells when naive but promotes their
survival and function once antigen expe-
rienced: a two-faced impact on autoim-
munity. Diabetes 57:2684–2692, 2008
4. Itoh N, Hanafusa T, Miyazaki A, Miya-
gawaJ,YamagataK,YamamotoK,Waguri
M, Imagawa A, Tamura S, Inada M:
Mononuclear cell inﬁltration and its rela-
tion to the expression of major histocom-
patibility complex antigens and adhesion
molecules in pancreas biopsy specimens
from newly diagnosed insulin-dependent
diabetes mellitus patients. J Clin Invest 92:
2313–2322, 1993
5. Herold KC, Hagopian W, Auger JA,
Poumian-Ruiz E, Taylor L, Donaldson D,
GitelmanSE,HarlanDM,XuD,ZivinRA,
Bluestone JA: Anti-CD3 monoclonal anti-
body in new-onset type 1 diabetes melli-
tus. N Engl J Med 346:1692–1698, 2002
Perspectives on the News
e4 DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009